Unknown

Dataset Information

0

Polyphenolic Proanthocyanidin-B2 suppresses proliferation of liver cancer cells and hepatocellular carcinogenesis through directly binding and inhibiting AKT activity.


ABSTRACT: The well-documented anticarcinogenic properties of natural polyphenolic proanthocyanidins (OPC) have been primarily attributed to their antioxidant and anti-inflammatory potency. Emerging evidence suggests that OPC may target canonical oncogenic pathways, including PI3K/AKT; however, the underlying mechanism and therapeutic potential remain elusive. Here we identify that proanthocyanidin B2 (OPC-B2) directly binds and inhibits AKT activity and downstream signalling, thereby suppressing tumour cell proliferation and metabolism in vitro and in a xenograft and diethyl-nitrosamine (DEN)-induced hepatocellular carcinoma (HCC) mouse models. We further find that OPC-B2 binds to the catalytic and regulatory PH domains to lock the protein in a closed conformation, similar to the well-studied AKT allosteric inhibitor MK-2206. Molecular docking and dynamic simulation suggest that Lys297 and Arg86 are critical sites of OPC-B2 binding; mutation of Lys297 or Arg86 to alanine completely abolishes the antitumor effects of OPC-B2 but not MK-2206. Together, our study reveals that OPC-B2 is a novel allosteric AKT inhibitor with potent anti-tumour efficacy beyond its antioxidant and anti-inflammatory properties.

SUBMITTER: Liu G 

PROVIDER: S-EPMC7472926 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Polyphenolic Proanthocyanidin-B2 suppresses proliferation of liver cancer cells and hepatocellular carcinogenesis through directly binding and inhibiting AKT activity.

Liu Guijun G   Shi Aimin A   Wang Ningning N   Li Min M   He Xuxiao X   Yin Chunzhao C   Tu Qiaochu Q   Shen Xia X   Tao Yongzhen Y   Wang Qiang Q   Yin Huiyong H  

Redox biology 20200825


The well-documented anticarcinogenic properties of natural polyphenolic proanthocyanidins (OPC) have been primarily attributed to their antioxidant and anti-inflammatory potency. Emerging evidence suggests that OPC may target canonical oncogenic pathways, including PI3K/AKT; however, the underlying mechanism and therapeutic potential remain elusive. Here we identify that proanthocyanidin B2 (OPC-B2) directly binds and inhibits AKT activity and downstream signalling, thereby suppressing tumour ce  ...[more]

Similar Datasets

| S-EPMC4427333 | biostudies-literature
| S-EPMC7579710 | biostudies-literature
| S-EPMC5587387 | biostudies-literature
| S-EPMC5975686 | biostudies-literature
| S-EPMC9650602 | biostudies-literature
| S-EPMC6525465 | biostudies-literature
| S-EPMC4414271 | biostudies-literature
| S-EPMC8085868 | biostudies-literature
| S-EPMC10133798 | biostudies-literature
| S-EPMC8716374 | biostudies-literature